Lannett Hits A High After Loss Of Levothyroxine
Company Plans To Launch Several New Products By End Of June
Despite reporting a 16.4% drop in turnover in its financial third quarter, Lannett says it has recorded the highest quarterly sales since a key levothyroxine distribution deal fell apart last year. The company has launched 14 products in the financial year so far and plans to launch several more.
